Mainz Biomed N.V (NASDAQ:MYNZ) shares, rose in value on Wednesday, June 18, with the stock price down by -3.16% to the previous day’s close as strong demand from buyers drove the stock to $1.53.
Actively observing the price movement in the last trading, the stock closed the session at $1.58, falling within a range of $1.465 and $1.5871. The value of beta (5-year monthly) was 0.305. Referring to stock’s 52-week performance, its high was $25.60, and the low was $1.55. On the whole, MYNZ has fluctuated by -30.77% over the past month.
With the market capitalization of Mainz Biomed N.V currently standing at about $5.84 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-31.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that MYNZ’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of MYNZ currently trading nearly -21.99% and -39.84% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 24.19, while the 7-day volatility ratio is showing 4.57% which for the 30-day chart, stands at 4.26%. Furthermore, Mainz Biomed N.V (MYNZ)’s beta value is 0.30, and its average true range (ATR) is 0.19.
A comparison of Mainz Biomed N.V (MYNZ) with its peers suggests the former has fared considerably weaker in the market. MYNZ showed an intraday change of -3.16% in last session, and over the past year, it shrunk by -93.88%%.
Data on historical trading for Mainz Biomed N.V (NASDAQ:MYNZ) indicates that the trading volumes over the past 10 days have averaged 69850.0 and over the past 3 months, they’ve averaged 169.92K. According to company’s latest data on outstanding shares, there are 3.81 million shares outstanding.
Nearly 3.35% of Mainz Biomed N.V’s shares belong to company insiders and institutional investors own 6.13% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 39353.0 shares as on 2025-05-30, resulting in a short ratio of 0.28. According to the data, the short interest in Mainz Biomed N.V (MYNZ) stood at 105.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 0.16 million. The stock has fallen by -64.58% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MYNZ stock heading into the next quarter.
